Drug intelligence / Profile preview

GSK2230672

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules
Administration: Oral

Overview

GSK2230672 is an investigational oral small molecule developed by GSK for the treatment of cholestasis. Its mechanism of action involves binding to and inhibiting the deubiquitinating activity of the enzyme Ubiquitin-specific protease 7 (USP7), which may modulate pathways relevant to cholestatic liver diseases. The drug has been evaluated in early-phase clinical trials, including dose-escalation studies in healthy volunteers[1][8].

Other names: gsk-2230672gsk2230672gsk 2230672

Targets

USP7

Beyond the preview

Go deeper on GSK2230672.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK2230672.

Explore the full profile